fashion -WSS

fashion

author：focus 2025-09-30 05:23:55 - browse：76

Three boxes of Breyanzi on a dark blue background — biotech coverage from STAT — The FDA is looking into adverse events involving a number of CAR-T therapies, including Breyanzi. Illustration: STAT; Source: Business Wire

The Food and Drug Administration said Tuesday that it is investigating whether CAR-T therapy, which uses genetically modified white blood cells to attack tumors, can in rare cases cause lymphoma, a blood cancer.

“Although the overall benefits of these products continue to outweigh their potential risks for their approved uses, FDA is investigating the identified risk of T cell malignancy with serious outcomes, including hospitalization and death, and is evaluating the need for regulatory action,” the agency said in a statement.

The agency noted that it is investigating reports of T cell lymphoma, including cancer cells carrying the engineered T cells, in patients who received CAR-T therapy. Experts in the field, which has produced multiple approved products to treat blood cancer, expressed surprise and puzzlement at the announcement, saying that they had not previously seen data about the risk.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： ASCO 2024: 'Reassuring' Corbus data on ADC bladder cancer drug

WSS

HIV drugs protect against transmission, even in unprotected sex

Woman returns to dialysis after doctors remove transplanted pig kidney

Ultragenyx gene therapy for rare liver ailment succeeds in late

ASCO Daily Recap: Safety data from Novartis, survival from Pfizer

Cord blood banking comes at a high cost to babies

With trial win, GSK could get blood cancer drug back on market

focus

fashion

entertainment

Drug repurposing or repositioning? The language matters

At ASCO, AstraZeneca reports strong data for breast cancer drug

Jerome Adams on the need for new antivirals for Covid

With trial win, GSK could get blood cancer drug back on market

Medical records are filled with copy

Change Healthcare can notify patients about the breach, HHS says

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Woman returns to dialysis after doctors remove transplanted pig kidney

State Dept. review finds Biden bears some blame for Afghanistan failures

Cord blood banking comes at a high cost to babies

focus

ASCO: AstraZeneca says CAR

With trial win, GSK could get blood cancer drug back on market

See how much Covid

Readout LOUD podcast: ASCO preview, a Duchenne trial failure

ASCO24: AstraZeneca won cancer’s big meeting. Can it fulfill its $80B ambition?

For one rare type of lung cancer, Pfizer pill reduces progression by 81%

hotspot

entertainment

focus

hotspot